This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Shu S. Lin Robert D. Davis Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Balsara, K. R. Articles by Welsby, I. J. Search for Related Content PubMed PubMed Citation Articles by Balsara, K. R. Articles by Welsby, I. J.

Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation

^a Department of Surgery, Box 3443, Duke University Medical Center, Durham, NC 27710, USA
^b Division of Cardiothoracic Anesthesia and Critical Care Medicine, Duke University Medical Center, Durham, NC, USA
^c Department of Immunology, Duke University Medical Center, Durham, NC, USA

*Corresponding author. Tel.: +1 (919) 970-2729; fax: +1 (919) 684-7263.

E-mail address: balsa001{at}mc.duke.edu (K.R. Balsara).

In lung transplants necessitating cardiopulmonary bypass (CPB), aprotinin has been shown to decrease transfusion requirements. More recently, off-pump transplantation has become the standard of care. The efficacy of aprotinin use in this population has yet to be definitively examined. We completed a retrospective review of all adult OP-BOLTs performed between January 2000 and January 2006 at a single university center (n=215). Aprotinin use was determined by the attending anesthesiologist or surgeon. It was administered at the time of induction. The primary outcome was total blood products utilized in terms of units transfused during postoperative days 0, 1 and 2. One-hundred and one patients received aprotinin and 114 did not. An overall analysis of all of the patients in this study demonstrated a trend towards statistical significance for reduced total blood product transfusion for the aprotinin group compared to the non-aprotinin group (P=0.13). A subgroup analysis was performed in relation to each diagnosis. The use of aprotinin was associated with a significant reduction in peri-operative total blood products transfused in COPD patients (P=0.03) undergoing OP-BOLT. Subgroup analysis demonstrated that the use of aprotinin in the COPD population did result in a statistically significant decrease in total blood products transfused, specifically the total number of units of packed red blood cells given. These findings suggest that aprotinin administration should be considered for all patients undergoing OP-BOLT to reduce exposure to blood products and potential immune sensitization and infectious complications.

Key Words: Blood loss; Lung transplantation; Postoperative complications; Aprotinin adverse effects; Blood transfusion

This article has been cited by other articles:

				S. F. Marasco, D. Pilcher, T. Oto, W. Chang, A. Griffiths, V. Pellegrino, J. Chan, and M. Bailey Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction Eur. J. Cardiothorac. Surg., February 1, 2010; 37(2): 420 - 425. [Abstract] [Full Text] [PDF]